Special Issue

Inorganic Phosphate Homeostasis and Signaling in Eukaryotic Cells

Message from the Guest Editors

Present in animals' cells, protozoa, fungi, and plants, inorganic phosphate (Pi) is involved in regulating a wide range of fundamental cellular processes, including energy homeostasis; nucleotide, nucleic acid, and phospholipid metabolism; and signaling through protein phosphorylation events. There is now vast evidence that Pi is associated with major pathological processes, including increased thrombotic risk in chronic kidney disease (CKD), renal fibrosis, angiogenesis, carcinogenesis, and tumor progression, but cellular and molecular mechanisms involved in regulating cellular Pi homeostasis and sensing changes in the extracellular and intracellular Pi concentrations are still elusive and merit further investigations. This Special Issue invites expertise in the field relating to cellular Pi homeostasis and signaling in eukaryotic cells with an overall aim to collate advanced knowledge around the field for a better and clearer understanding of cellular Pi sensing, signaling, and pathologies which may arise from anomalies in cellular Pi homeostasis.

Guest Editors

Dr. Nima Abbasian

Domainex Ltd, Unit 2, Iconix Park, London Road, Pampisford, Cambridge, CB22 3EG, UK

Dr. Alan Bevington

Biochemistry (Renal Medicine), University of Leicester, Leicester, UK

Deadline for manuscript submissions

closed (30 September 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/69041

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).